SCA
PLX icon

Snowden Capital Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Snowden Capital Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed – – 1791
2021
Q4 		$0 Buy
+500
New +$524 ﹤0.01% 2116

Other funds holding PLX

PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Snowden Capital Advisors's PLX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Protalix BioTherapeutics (PLX) in Q1 2022, closing a stake of 500 shares.

Snowden Capital Advisors first reported a position in PLX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 32 funds tracked by Wall St. Rank hold PLX as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Protalix BioTherapeutics position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 500 Protalix BioTherapeutics shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Protalix BioTherapeutics in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Protalix BioTherapeutics position peaked at $0 in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.